Novel metabolic biomarker for early detection and diagnosis to the patients with gastric cardia adenocarcinoma.
HER2
bile acid
gastric cardia adenocarcinoma
metabolomics
stage
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
10
01
2024
received:
06
11
2023
accepted:
31
01
2024
medline:
18
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
ppublish
Résumé
Gastric cardia adenocarcinoma (GCA) is classified as Siewert type II adenocarcinoma at the esophagogastric junction in Western countries. The majority of GCA patients do not exhibit early warning symptoms, leading to over 90% of diagnoses at an advanced stage, resulting in a grim prognosis, with less than a 20% 5-year survival rate. Metabolic features of 276 GCA and 588 healthy controls were characterized through a widely-targeted metabolomics by UPLC-MS/MS analysis. This study encompasses a joint pathway analysis utilizing identified metabolites, survival analysis in both early and advanced stages, as well as high and negative and low expression of HER2 immunohistochemistry staining. Machine learning techniques and Cox regression models were employed to construct a diagnostic panel. A total of 25 differential metabolites were consistently identified in both discovery and validation sets based on criteria of p < 0.05, (VIP) ≥ 1, and FC ≥ 2 or FC ≤ 0.5. Early-stage GCA patients exhibited a more favorable prognosis compared to those in advanced stages. HER2 overexpression was associated with a more positive outcome compared to the negative and low expression groups. Metabolite panel demonstrated a robust diagnostic performance with AUC of 0.869 in discovery set and 0.900 in validation set. A total of 25 common and stable differential metabolites may hold promise as liquid non-invasive indicators for GCA diagnosis. HER2 may function as a tumor suppressor gene in GCA, as its overexpression is associated with improved survival. The downregulation of bile acid metabolism in GCA may offer valuable theoretical insights and innovative approaches for precision-targeted treatments in GCA patients.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cardia adenocarcinoma (GCA) is classified as Siewert type II adenocarcinoma at the esophagogastric junction in Western countries. The majority of GCA patients do not exhibit early warning symptoms, leading to over 90% of diagnoses at an advanced stage, resulting in a grim prognosis, with less than a 20% 5-year survival rate.
METHOD
METHODS
Metabolic features of 276 GCA and 588 healthy controls were characterized through a widely-targeted metabolomics by UPLC-MS/MS analysis. This study encompasses a joint pathway analysis utilizing identified metabolites, survival analysis in both early and advanced stages, as well as high and negative and low expression of HER2 immunohistochemistry staining. Machine learning techniques and Cox regression models were employed to construct a diagnostic panel.
RESULTS
RESULTS
A total of 25 differential metabolites were consistently identified in both discovery and validation sets based on criteria of p < 0.05, (VIP) ≥ 1, and FC ≥ 2 or FC ≤ 0.5. Early-stage GCA patients exhibited a more favorable prognosis compared to those in advanced stages. HER2 overexpression was associated with a more positive outcome compared to the negative and low expression groups. Metabolite panel demonstrated a robust diagnostic performance with AUC of 0.869 in discovery set and 0.900 in validation set.
CONCLUSIONS
CONCLUSIONS
A total of 25 common and stable differential metabolites may hold promise as liquid non-invasive indicators for GCA diagnosis. HER2 may function as a tumor suppressor gene in GCA, as its overexpression is associated with improved survival. The downregulation of bile acid metabolism in GCA may offer valuable theoretical insights and innovative approaches for precision-targeted treatments in GCA patients.
Identifiants
pubmed: 38491808
doi: 10.1002/cam4.7015
pmc: PMC10943274
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7015Subventions
Organisme : National Natural Science Foundation of China
ID : 81872032
Organisme : Medical Science and Technology Research Plan Joint Construction Project of Henan Province
ID : LHGJ20210336
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
PLoS One. 2018 May 21;13(5):e0197765
pubmed: 29782543
PLoS One. 2017 Jan 10;12(1):e0169567
pubmed: 28072830
Clin Transl Med. 2023 Jan;13(1):e1180
pubmed: 36639836
Nature. 2008 Mar 13;452(7184):230-3
pubmed: 18337823
World J Gastroenterol. 2003 Jun;9(6):1156-64
pubmed: 12800215
Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):885-93
pubmed: 26651250
Dig Dis Sci. 2007 Feb;52(2):531-5
pubmed: 17211707
Xenobiotica. 1999 Nov;29(11):1181-9
pubmed: 10598751
Int J Cancer. 2021 Nov 1;149(9):1639-1648
pubmed: 34181269
Metabolomics. 2010 Mar;6(1):3-17
pubmed: 20339444
Nat Rev Cancer. 2007 May;7(5):389-97
pubmed: 17446858
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
Oncol Lett. 2020 Jan;19(1):681-690
pubmed: 31897184
Medicine (Baltimore). 2019 Dec;98(50):e18397
pubmed: 31852158
Mov Disord. 2017 Oct;32(10):1401-1408
pubmed: 28843022
Metabolomics. 2017;13(12):151
pubmed: 29142509
J Clin Oncol. 2010 Dec 10;28(35):5219-28
pubmed: 20975063
Expert Rev Mol Diagn. 2019 Sep;19(9):785-793
pubmed: 31414918
Mol Neurobiol. 2018 Aug;55(8):6319-6328
pubmed: 29294246
Clin Exp Med. 2010 Dec;10(4):215-9
pubmed: 20454995
Cell Mol Life Sci. 2022 Apr 16;79(5):243
pubmed: 35429253
FEBS Open Bio. 2021 Sep;11(9):2525-2540
pubmed: 34231338
Diabetes. 2013 May;62(5):1730-7
pubmed: 23160532
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1967-71
pubmed: 16103445
Neurobiol Dis. 2019 Mar;123:42-58
pubmed: 29782966
Life Sci. 2020 Apr 15;247:117443
pubmed: 32084434
Mol Neurobiol. 2016 Jan;53(1):254-269
pubmed: 25428622
Metabolomics. 2022 Apr 19;18(5):26
pubmed: 35441991
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Cancer Res. 2016 Feb 15;76(4):796-804
pubmed: 26685161
Carcinogenesis. 2014 Mar;35(3):515-27
pubmed: 24343361
J Physiol Pharmacol. 2002 Mar;53(1):39-50
pubmed: 11939718
Am J Gastroenterol. 2018 Oct;113(10):1428
pubmed: 29899434
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Proc Nutr Soc. 2004 Feb;63(1):49-63
pubmed: 15099407
J Intern Med. 2018 Dec;284(6):643-663
pubmed: 30051512
J Ethnopharmacol. 2003 Oct;88(2-3):269-73
pubmed: 12963154
Front Oncol. 2022 Jan 20;11:778258
pubmed: 35127481
Gut Microbes. 2016 May 3;7(3):201-15
pubmed: 27003186
Cancer Metastasis Rev. 2015 Mar;34(1):145-55
pubmed: 25721950
J Thorac Oncol. 2020 Apr;15(4):649-654
pubmed: 31863848
Dig Dis Sci. 2008 Aug;53(8):2101-5
pubmed: 18231859
Basic Clin Pharmacol Toxicol. 2017 Mar;120(3):303-311
pubmed: 27730746
Int J Colorectal Dis. 2003 Jul;18(4):320-9
pubmed: 12774247